Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth (Status and Outlook) 2026-2032
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key ESR1 Mutated Metastatic Breast Cancer Diagnostics players cover APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Forecast? looks at past sales and reviews total world ESR1 Mutated Metastatic Breast Cancer Diagnostics sales in 2025, providing a comprehensive analysis by region and market sector of projected ESR1 Mutated Metastatic Breast Cancer Diagnostics sales for 2026 through 2032. With ESR1 Mutated Metastatic Breast Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ESR1 Mutated Metastatic Breast Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on ESR1 Mutated Metastatic Breast Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global ESR1 Mutated Metastatic Breast Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ESR1 Mutated Metastatic Breast Cancer Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of ESR1 Mutated Metastatic Breast Cancer Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
United States market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key ESR1 Mutated Metastatic Breast Cancer Diagnostics players cover APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Forecast? looks at past sales and reviews total world ESR1 Mutated Metastatic Breast Cancer Diagnostics sales in 2025, providing a comprehensive analysis by region and market sector of projected ESR1 Mutated Metastatic Breast Cancer Diagnostics sales for 2026 through 2032. With ESR1 Mutated Metastatic Breast Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ESR1 Mutated Metastatic Breast Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on ESR1 Mutated Metastatic Breast Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global ESR1 Mutated Metastatic Breast Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ESR1 Mutated Metastatic Breast Cancer Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of ESR1 Mutated Metastatic Breast Cancer Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- NGS Based
- PCR Based
- Hospital Associated Labs
- lndependent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research lnstitutes
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- APIS Assay Technologies
- lllumina, Inc.
- GENCURIX
- RainSure Scientific
- NeoGenomics Laboratories
- Sysmex Corporation
- ASURAGEN,INC
- Guardant Health
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2021-2032)
2.1.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for ESR1 Mutated Metastatic Breast Cancer Diagnostics by Country/Region (2021, 2025 & 2032)
2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type
2.2.1 NGS Based
2.2.2 PCR Based
2.2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type
2.2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application
2.3.1 Hospital Associated Labs
2.3.2 lndependent Diagnostic Laboratories
2.3.3 Diagnostic Imaging Centers
2.3.4 Cancer Research lnstitutes
2.3.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application
2.3.5.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
3 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Player
3.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Player (2021-2026)
3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player (2021-2026)
3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS BY REGION
4.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Annual Revenue by Country/Region (2021-2026)
4.3 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.4 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.5 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.6 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
5.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
5.3 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
6.2 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
6.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics by Region (2021-2026)
8.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
8.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.1.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2027-2032)
10.2.1 United States Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.2 Canada Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.3 Mexico Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.4 Brazil Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.3.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast
10.3.2 Japan Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.3 Korea Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.4 Southeast Asia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.5 India Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.6 Australia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2027-2032)
10.4.1 Germany Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.2 France Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.3 UK Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.4 Italy Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.5 Russia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.5.1 Egypt Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.2 South Africa Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.3 Israel Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.4 Turkey Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.6 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Type (2027-2032)
10.7 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
11 KEY PLAYERS ANALYSIS
11.1 APIS Assay Technologies
11.1.1 APIS Assay Technologies Company Information
11.1.2 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 APIS Assay Technologies Main Business Overview
11.1.5 APIS Assay Technologies Latest Developments
11.2 lllumina, Inc.
11.2.1 lllumina, Inc. Company Information
11.2.2 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 lllumina, Inc. Main Business Overview
11.2.5 lllumina, Inc. Latest Developments
11.3 GENCURIX
11.3.1 GENCURIX Company Information
11.3.2 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 GENCURIX Main Business Overview
11.3.5 GENCURIX Latest Developments
11.4 RainSure Scientific
11.4.1 RainSure Scientific Company Information
11.4.2 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 RainSure Scientific Main Business Overview
11.4.5 RainSure Scientific Latest Developments
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Information
11.5.2 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 NeoGenomics Laboratories Main Business Overview
11.5.5 NeoGenomics Laboratories Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 ASURAGEN,INC
11.7.1 ASURAGEN,INC Company Information
11.7.2 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 ASURAGEN,INC Main Business Overview
11.7.5 ASURAGEN,INC Latest Developments
11.8 Guardant Health
11.8.1 Guardant Health Company Information
11.8.2 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Guardant Health Main Business Overview
11.8.5 Guardant Health Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2021-2032)
2.1.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for ESR1 Mutated Metastatic Breast Cancer Diagnostics by Country/Region (2021, 2025 & 2032)
2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type
2.2.1 NGS Based
2.2.2 PCR Based
2.2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type
2.2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application
2.3.1 Hospital Associated Labs
2.3.2 lndependent Diagnostic Laboratories
2.3.3 Diagnostic Imaging Centers
2.3.4 Cancer Research lnstitutes
2.3.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application
2.3.5.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
3 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET SIZE BY PLAYER
3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Player
3.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Player (2021-2026)
3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player (2021-2026)
3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS BY REGION
4.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Annual Revenue by Country/Region (2021-2026)
4.3 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.4 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.5 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
4.6 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
5.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
5.3 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
6.2 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
6.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics by Region (2021-2026)
8.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026)
8.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ESR1 MUTATED METASTATIC BREAST CANCER DIAGNOSTICS MARKET FORECAST
10.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.1.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.1.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2 Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2027-2032)
10.2.1 United States Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.2 Canada Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.3 Mexico Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.2.4 Brazil Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3 APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.3.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast
10.3.2 Japan Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.3 Korea Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.4 Southeast Asia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.5 India Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.3.6 Australia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Country (2027-2032)
10.4.1 Germany Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.2 France Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.3 UK Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.4 Italy Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.4.5 Russia Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Region (2027-2032)
10.5.1 Egypt Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.2 South Africa Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.3 Israel Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.5.4 Turkey Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
10.6 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Type (2027-2032)
10.7 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecast
11 KEY PLAYERS ANALYSIS
11.1 APIS Assay Technologies
11.1.1 APIS Assay Technologies Company Information
11.1.2 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 APIS Assay Technologies Main Business Overview
11.1.5 APIS Assay Technologies Latest Developments
11.2 lllumina, Inc.
11.2.1 lllumina, Inc. Company Information
11.2.2 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 lllumina, Inc. Main Business Overview
11.2.5 lllumina, Inc. Latest Developments
11.3 GENCURIX
11.3.1 GENCURIX Company Information
11.3.2 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 GENCURIX Main Business Overview
11.3.5 GENCURIX Latest Developments
11.4 RainSure Scientific
11.4.1 RainSure Scientific Company Information
11.4.2 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 RainSure Scientific Main Business Overview
11.4.5 RainSure Scientific Latest Developments
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Information
11.5.2 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 NeoGenomics Laboratories Main Business Overview
11.5.5 NeoGenomics Laboratories Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 ASURAGEN,INC
11.7.1 ASURAGEN,INC Company Information
11.7.2 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 ASURAGEN,INC Main Business Overview
11.7.5 ASURAGEN,INC Latest Developments
11.8 Guardant Health
11.8.1 Guardant Health Company Information
11.8.2 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Guardant Health Main Business Overview
11.8.5 Guardant Health Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. ESR1 Mutated Metastatic Breast Cancer Diagnostics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NGS Based
Table 4. Major Players of PCR Based
Table 5. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 8. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 10. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Player (2021-2026) & ($ millions)
Table 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player (2021-2026)
Table 13. ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered
Table 14. ESR1 Mutated Metastatic Breast Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 23. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 27. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 29. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 33. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 39. Key Market Challenges & Risks of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 40. Key Industry Trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 41. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. APIS Assay Technologies Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 46. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 47. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. APIS Assay Technologies Main Business
Table 49. APIS Assay Technologies Latest Developments
Table 50. lllumina, Inc. Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 51. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 52. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. lllumina, Inc. Main Business
Table 54. lllumina, Inc. Latest Developments
Table 55. GENCURIX Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 56. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 57. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. GENCURIX Main Business
Table 59. GENCURIX Latest Developments
Table 60. RainSure Scientific Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 61. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 62. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. RainSure Scientific Main Business
Table 64. RainSure Scientific Latest Developments
Table 65. NeoGenomics Laboratories Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 66. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 67. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. NeoGenomics Laboratories Main Business
Table 69. NeoGenomics Laboratories Latest Developments
Table 70. Sysmex Corporation Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 71. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 72. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Sysmex Corporation Main Business
Table 74. Sysmex Corporation Latest Developments
Table 75. ASURAGEN,INC Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 76. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 77. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. ASURAGEN,INC Main Business
Table 79. ASURAGEN,INC Latest Developments
Table 80. Guardant Health Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 81. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 82. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Guardant Health Main Business
Table 84. Guardant Health Latest Developments
Table 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. ESR1 Mutated Metastatic Breast Cancer Diagnostics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NGS Based
Table 4. Major Players of PCR Based
Table 5. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 8. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 10. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Player (2021-2026) & ($ millions)
Table 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player (2021-2026)
Table 13. ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Products Offered
Table 14. ESR1 Mutated Metastatic Breast Cancer Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 23. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Table 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Table 27. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Table 29. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country (2021-2026)
Table 33. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 39. Key Market Challenges & Risks of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 40. Key Industry Trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics
Table 41. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. APIS Assay Technologies Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 46. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 47. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. APIS Assay Technologies Main Business
Table 49. APIS Assay Technologies Latest Developments
Table 50. lllumina, Inc. Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 51. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 52. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. lllumina, Inc. Main Business
Table 54. lllumina, Inc. Latest Developments
Table 55. GENCURIX Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 56. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 57. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. GENCURIX Main Business
Table 59. GENCURIX Latest Developments
Table 60. RainSure Scientific Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 61. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 62. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. RainSure Scientific Main Business
Table 64. RainSure Scientific Latest Developments
Table 65. NeoGenomics Laboratories Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 66. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 67. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. NeoGenomics Laboratories Main Business
Table 69. NeoGenomics Laboratories Latest Developments
Table 70. Sysmex Corporation Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 71. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 72. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Sysmex Corporation Main Business
Table 74. Sysmex Corporation Latest Developments
Table 75. ASURAGEN,INC Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 76. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 77. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. ASURAGEN,INC Main Business
Table 79. ASURAGEN,INC Latest Developments
Table 80. Guardant Health Details, Company Type, ESR1 Mutated Metastatic Breast Cancer Diagnostics Area Served and Its Competitors
Table 81. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Offered
Table 82. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Guardant Health Main Business
Table 84. Guardant Health Latest Developments
LIST OF FIGURES
Figure 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2025)
Figure 8. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type in 2025
Figure 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs
Figure 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Hospital Associated Labs (2021-2026) & ($ millions)
Figure 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics in lndependent Diagnostic Laboratories
Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: lndependent Diagnostic Laboratories (2021-2026) & ($ millions)
Figure 14. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Diagnostic Imaging Centers
Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Diagnostic Imaging Centers (2021-2026) & ($ millions)
Figure 16. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Cancer Research lnstitutes
Figure 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Cancer Research lnstitutes (2021-2026) & ($ millions)
Figure 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application in 2025
Figure 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player in 2025
Figure 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 22. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Value Market Share by Country in 2025
Figure 26. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region in 2025
Figure 31. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 32. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 33. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 37. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country in 2025
Figure 40. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 41. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 42. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 43. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 56. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 57. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 59. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 60. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 61. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 62. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 63. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 64. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 65. Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 67. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 68. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 69. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 70. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 71. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 72. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 73. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 74. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 75. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 76. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 77. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 78. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2025)
Figure 8. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type in 2025
Figure 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs
Figure 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Hospital Associated Labs (2021-2026) & ($ millions)
Figure 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics in lndependent Diagnostic Laboratories
Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: lndependent Diagnostic Laboratories (2021-2026) & ($ millions)
Figure 14. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Diagnostic Imaging Centers
Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Diagnostic Imaging Centers (2021-2026) & ($ millions)
Figure 16. ESR1 Mutated Metastatic Breast Cancer Diagnostics in Cancer Research lnstitutes
Figure 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Cancer Research lnstitutes (2021-2026) & ($ millions)
Figure 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application in 2025
Figure 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Player in 2025
Figure 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 21. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 22. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2021-2026 ($ millions)
Figure 25. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Value Market Share by Country in 2025
Figure 26. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region in 2025
Figure 31. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 32. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 33. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 37. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Country in 2025
Figure 40. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 41. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 42. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 43. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 56. APAC ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 57. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 59. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 60. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 61. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 62. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 63. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 64. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 65. Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 67. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 68. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 69. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 70. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 71. UK ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 72. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 73. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 74. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 75. South Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 76. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 77. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
Figure 78. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size 2027-2032 ($ millions)
